Department of Nephrology, The Third Affiliated Hospital of Sun Yat-sen University, Tianhe Road 600#, Guangzhou, 510630, People's Republic of China.
Int Urol Nephrol. 2020 May;52(5):943-951. doi: 10.1007/s11255-020-02448-4. Epub 2020 Apr 1.
To investigate the effect of cardiac valve calcification (CVC) on all-cause and cardiovascular mortality in maintenance hemodialysis (MHD) patients.
A retrospective cohort study was conducted in 183 long-term hemodialysis patients with complete follow-up data from January 1, 2012, to December 30, 2015. The baseline data between CVC and non-CVC groups were compared. Kaplan-Meier method was used to analyze all-cause and cardiovascular mortality. The effect of CVC on prognosis was analyzed using the Cox proportional hazard regression model and subgroup analysis.
Among 183 patients under hemodialysis, 104 (56.8%) were males, with an average age of 56.1 ± 17.0 years and 68 (37.2%) were complicated with valvular calcification. The median follow-up period was 30.8 months. All-cause and cardiovascular mortality were 50% vs. 14.8% and 25% vs. 7.0% in the CVC and non-CVC groups, respectively (P < 0.05). Kaplan-Meier indicated that differences in all-cause and cardiovascular mortality were statistically significant between the two groups (P < 0.001). Cox regression analysis showed that CVC significantly increased all-cause (hazards ratio [HR] 2.161 [1.083-4.315]) and cardiovascular mortality (3.435 [1.222-9.651]) after adjusting for multiple factors. Meanwhile, CVC also increases the incidence of new-onset cardiovascular events. Subgroup analysis revealed that all-cause and cardiovascular mortality were significantly higher in patients with aortic valve calcification (AVC) than in patients with mitral valve calcification (MVC). Multivariate calibration showed that AVC increased the risk of cardiovascular death (HR 5.486 [1.802-16.702]) (P < 0.05), whereas MVC did not. By further comparing the echocardiographic data of the two groups, the incidence of LVH and pulmonary hypertension in the AVC group was significantly higher than that in the MVC group.
Valve calcification increases the risk of all-cause and cardiovascular mortality in MHD patients, also new-onset cardiovascular events, and aortic valve calcification contributes more to the risk of cardiovascular mortality.
探讨心脏瓣膜钙化(CVC)对维持性血液透析(MHD)患者全因和心血管死亡率的影响。
对 2012 年 1 月 1 日至 2015 年 12 月 30 日期间接受完整随访的 183 例长期血液透析患者进行回顾性队列研究。比较 CVC 组与非 CVC 组的基线数据。Kaplan-Meier 法分析全因和心血管死亡率。Cox 比例风险回归模型和亚组分析用于分析 CVC 对预后的影响。
在 183 名血液透析患者中,男性 104 例(56.8%),平均年龄为 56.1±17.0 岁,68 例(37.2%)并发瓣膜钙化。中位随访时间为 30.8 个月。CVC 组和非 CVC 组的全因死亡率和心血管死亡率分别为 50%比 14.8%和 25%比 7.0%(P<0.05)。Kaplan-Meier 表明两组之间的全因死亡率和心血管死亡率差异有统计学意义(P<0.001)。Cox 回归分析显示,在校正多种因素后,CVC 显著增加全因(风险比[HR]2.161[1.083-4.315])和心血管死亡率(3.435[1.222-9.651])。同时,CVC 还增加了新发心血管事件的发生率。亚组分析显示,主动脉瓣钙化(AVC)患者的全因死亡率和心血管死亡率明显高于二尖瓣钙化(MVC)患者。多变量校准显示,AVC 增加了心血管死亡的风险(HR 5.486[1.802-16.702])(P<0.05),而 MVC 则没有。通过进一步比较两组的超声心动图数据,AVC 组的左心室肥厚和肺动脉高压发生率明显高于 MVC 组。
瓣膜钙化增加了 MHD 患者全因和心血管死亡率以及新发心血管事件的风险,主动脉瓣钙化对心血管死亡率的风险贡献更大。